Table 1.
Characteristics of studies included.
| No | First Author | Study Type | Country | N | Age (Years) | Adult, n | Male, n | Types of Hemoglobinopathy | Mortality, n | |
|---|---|---|---|---|---|---|---|---|---|---|
| SCD, n | Thal, n | |||||||||
| 1 | Albagshi M (8) | Case Series | Saudi Arabia | 2 | 37 | 2 | 1 | 2 | 0 | 0 |
| 2 | Al-Hebshi A (9) | Case Series | Saudi Arabia | 3 | 42.667 | 1 | 1 | 3 | 0 | 0 |
| 3 | Allison D (10) | Case Report | United States | 1 | 27 | 1 | 1 | 1 | 0 | 0 |
| 4 | Appiah-Kubi A (11) | Case Series | United States | 7 | 14.286 | 2 | 2 | 7 | 0 | 0 |
| 5 | Arlet JB (12) | Case Series | France | 83 | Adult: 33.5 (median) Child: 12.0 (median) |
66 | 38 | 83 | 0 | 2 |
| 6 | Balanchivadze N (13) | Case Series | United States | 24 | 52.9 | 24 | 6 | 24 | 0 | 1 |
| 7 | Beerkens F (14) | Case Report | United States | 1 | 21 | 1 | 1 | 1 | 0 | 0 |
| 8 | Dagalakis U (15) | Case Report | United States | 1 | 0.5 | 0 | 1 | 1 | 0 | 0 |
| 9 | De Luna G (16) | Case Report | France | 1 | 45 | 1 | 1 | 1 | 0 | 0 |
| 10 | De Sanctis V (17) | Case Series | Multi-nation§ | 13 | 33.7 | 12 | 4 | 3 | 10 | 1 |
| 11 | Ershler WB (18) | Case Report | United States | 1 | 39 | 1 | 0 | 1 | 0 | 0 |
| 12 | Fronza M (19) | Case Report | Italy | 1 | 44 | 1 | 0 | 1 | 0 | 0 |
| 13 | Heilbronner (20) | Case Series | France | 4 | 14.55 | 0 | 1 | 4 | 0 | 0 |
| 14 | Hussain FA (21) | Case Series | United States | 4 | 33 | 4 | 2 | 4 | 0 | 0 |
| 15 | Jacob S (22) | Case Study | United States | 1 | 2.75 | 0 | 1 | 1 | 0 | 0 |
| 16 | Justino (23) | Case Study | Brazil | 1 | 35 | 1 | 0 | 1 | 0 | 0 |
| 17 | Karimi M (24) | Cohort | Iran | 15 | 36 | 15 | 7 | 0 | 15 | 4 |
| 18 | Karimi M (25) | Cohort | Iran | 43 | 35.3 | 42 | 22 | 0 | 43 | 8 |
| 19 | Marhaeni W (26) | Case Report | Indonesia | 1 | 17 | 0 | 0 | 0 | 1 | 0 |
| 20 | Marziali M (27) | Case Report | Italy | 1 | 46 | 1 | 1 | 0 | 1 | 0 |
| 21 | Morrone KA (28) | Case Series | United States | 8 | 16 | 2 | 4 | 8 | 0 | 0 |
| 22 | Motta I (29) | Case Series | Italy | 11 | 44.27 | 11 | 5 | 0 | 11 | 0 |
| 23 | Nur E (30) | Case Series | Netherlands | 2 | 22 | 2 | 1 | 2 | 0 | 0 |
| 24 | Odievre MH (31) | Case Report | Netherlands | 1 | 16 | 0 | 0 | 1 | 0 | 0 |
| 25 | Okar L (32) | Case Report | Qatar | 1 | 25 | 1 | 0 | 0 | 1 | 0 |
| 26 | Pinto VM (33) | Case Report | Italy | 1 | 57 | 1 | 1 | 0 | 1 | 0 |
| 27 | Sasi S (34) | Case Report | Qatar | 1 | 26 | 1 | 1 | 0 | 1* | 0 |
| 28 | Sheha D (35) | Case Report | Egypt | 1 | 22 | 1 | 0 | 1 | 0 | 0 |
| 29 | Stochino C (36) | Case Series | Italy | 1 | 20 | 1 | 0 | 1 | 0 | 0 |
| 30 | Subarna C (37) | Case Series | United Kingdom | 10 | 38.25 | 10 | 3 | 10 | 0 | 1 |
| 31 | Verdiyeva N (38) | Case Report | Russia | 1 | 24 | 1 | 1 | 1 | 0 | 0 |
SCD, sickle cell disease; Thal, thalassemia; N, number.
§
Turkey, Italy, Cyprus, Iran, Oman, Azerbaijan.
*
Hemoglobin D disease.